- Home
- RVPHW vs GES Comparison
RVPHW vs GES Comparison
Compare RVPHW & GES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- GES
- Stock Information
- Founded
- RVPHW N/A
- GES 1981
- Country
- RVPHW United States
- GES United States
- Employees
- RVPHW 15
- GES N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- GES Apparel
- Sector
- RVPHW Health Care
- GES Consumer Discretionary
- Exchange
- RVPHW Nasdaq
- GES Nasdaq
- Market Cap
- RVPHW N/A
- GES N/A
- IPO Year
- RVPHW 2018
- GES 1996
- Fundamental
- Price
- RVPHW $0.19
- GES $16.78
- Analyst Decision
- RVPHW
- GES Buy
- Analyst Count
- RVPHW 0
- GES 6
- Target Price
- RVPHW N/A
- GES $28.50
- AVG Volume (30 Days)
- RVPHW N/A
- GES 792.1K
- Earning Date
- RVPHW N/A
- GES 11-26-2024
- Dividend Yield
- RVPHW N/A
- GES 7.16%
- EPS Growth
- RVPHW N/A
- GES 30.70
- EPS
- RVPHW N/A
- GES 2.93
- Revenue
- RVPHW N/A
- GES $2,866,723,000.00
- Revenue This Year
- RVPHW N/A
- GES $11.11
- Revenue Next Year
- RVPHW N/A
- GES $4.76
- P/E Ratio
- RVPHW N/A
- GES $5.72
- Revenue Growth
- RVPHW N/A
- GES 6.75
- 52 Week Low
- RVPHW N/A
- GES $16.67
- 52 Week High
- RVPHW N/A
- GES $33.50
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- GES 34.54
- Support Level
- RVPHW N/A
- GES $17.09
- Resistance Level
- RVPHW N/A
- GES $17.55
- Average True Range (ATR)
- RVPHW 0.00
- GES 0.42
- MACD
- RVPHW 0.00
- GES 0.03
- Stochastic Oscillator
- RVPHW 0.00
- GES 9.17
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.